Cargando…
Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier
In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as cl...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861254/ https://www.ncbi.nlm.nih.gov/pubmed/36678814 http://dx.doi.org/10.3390/pharmaceutics15010185 |
_version_ | 1784874795493490688 |
---|---|
author | Salvador, Ellaine Köppl, Theresa Hörmann, Julia Schönhärl, Sebastian Bugaeva, Polina Kessler, Almuth F. Burek, Malgorzata Ernestus, Ralf-Ingo Löhr, Mario Hagemann, Carsten |
author_facet | Salvador, Ellaine Köppl, Theresa Hörmann, Julia Schönhärl, Sebastian Bugaeva, Polina Kessler, Almuth F. Burek, Malgorzata Ernestus, Ralf-Ingo Löhr, Mario Hagemann, Carsten |
author_sort | Salvador, Ellaine |
collection | PubMed |
description | In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as claudin-5 from the membrane to the cytoplasm. In investigating the possibility that the same effects could be observed in human-derived cells, a 3D co-culture model of the BBB was established consisting of primary microvascular brain endothelial cells (HBMVEC) and immortalized pericytes, both of human origin. The TTFields at a frequency of 100 kHz administered for 72 h increased the permeability of our human-derived BBB model. The integrity of the BBB had already recovered 48 h post-TTFields, which is earlier than that observed in cerebEND. The data presented herein validate the previously observed effects of TTFields in murine models. Moreover, due to the fact that human cell-based in vitro models more closely resemble patient-derived entities, our findings are highly relevant for pre-clinical studies. |
format | Online Article Text |
id | pubmed-9861254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98612542023-01-22 Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier Salvador, Ellaine Köppl, Theresa Hörmann, Julia Schönhärl, Sebastian Bugaeva, Polina Kessler, Almuth F. Burek, Malgorzata Ernestus, Ralf-Ingo Löhr, Mario Hagemann, Carsten Pharmaceutics Article In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as claudin-5 from the membrane to the cytoplasm. In investigating the possibility that the same effects could be observed in human-derived cells, a 3D co-culture model of the BBB was established consisting of primary microvascular brain endothelial cells (HBMVEC) and immortalized pericytes, both of human origin. The TTFields at a frequency of 100 kHz administered for 72 h increased the permeability of our human-derived BBB model. The integrity of the BBB had already recovered 48 h post-TTFields, which is earlier than that observed in cerebEND. The data presented herein validate the previously observed effects of TTFields in murine models. Moreover, due to the fact that human cell-based in vitro models more closely resemble patient-derived entities, our findings are highly relevant for pre-clinical studies. MDPI 2023-01-04 /pmc/articles/PMC9861254/ /pubmed/36678814 http://dx.doi.org/10.3390/pharmaceutics15010185 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salvador, Ellaine Köppl, Theresa Hörmann, Julia Schönhärl, Sebastian Bugaeva, Polina Kessler, Almuth F. Burek, Malgorzata Ernestus, Ralf-Ingo Löhr, Mario Hagemann, Carsten Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier |
title | Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier |
title_full | Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier |
title_fullStr | Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier |
title_full_unstemmed | Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier |
title_short | Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier |
title_sort | tumor treating fields (ttfields) induce cell junction alterations in a human 3d in vitro model of the blood-brain barrier |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861254/ https://www.ncbi.nlm.nih.gov/pubmed/36678814 http://dx.doi.org/10.3390/pharmaceutics15010185 |
work_keys_str_mv | AT salvadorellaine tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT koppltheresa tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT hormannjulia tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT schonharlsebastian tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT bugaevapolina tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT kessleralmuthf tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT burekmalgorzata tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT ernestusralfingo tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT lohrmario tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier AT hagemanncarsten tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier |